On October 2, INSILICO fell 5.16% in regular trading, trading at 57.25 HKD/share, with turnover of approximately 15.88 million HKD. The decline occurred amid broad selling pressure across the Life Sciences Tools & Services sector, with WUXI APPTEC down 2.7%, WUXI BIO down 1.52%, GENSCRIPT BIO down 1.96%, WUXI XDC down 3.17%, and XTALPI down 4.77%.

The pullback follows a sharp 8.48% surge on October 1, when the stock rallied to 60.1 HKD on heavy volume of over 1 billion HKD. That session's gains were fueled by the company's nomination of ISM1354, a next-generation small-molecule GIPR antagonist as a preclinical candidate for obesity and type 2 diabetes, as well as sustained market enthusiasm around a recently announced multi-tens-of-millions-dollar AI model co-development partnership. The stock had also benefited from a series of positive catalysts in September, including the dosing of the first patient in its Phase III trial for Rentosertib and chairman share purchases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)